This website uses cookies By using our website you consent to all cookies in accordance with our Cookie Policy. Read more Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links. We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable. Healthcare ProfessionalsCustomersSuppliersGEP-NET Trials Home Company Therapy Pipeline Products News Events Career Diversity Contact Newsticker Previous ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. Lutetium-177-Edotreotide for Neuroendocrine Tumors at NANETS Annual Symposium 2021 ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225 ITM Announces Completion of Conversion into SE Next Inside Stories OUR COMPANY More PIPELINE In Targeted Cancer Diagnostics & Therapy CAREER Be Part Of Our Company TARGETED RADIONUCLIDE THERAPY In Precision Oncology PRODUCTS Radiopharmaceutical & Radioisotope Business DIVERSITY Diversity at ITM Trending Neuroendocrine Tumors (GEP-NETs) Glioblastoma Osteosarcoma Osteoblastic Bone Metastases Folate Receptor α+ Tumors PIPELINE UPDATE: Innovative theranostic candidates in Precision Oncology Disclaimer Imprint General Terms & Conditions Privacy Policy Community Guidelines Sitemap Search